XML 57 R46.htm IDEA: XBRL DOCUMENT
v3.26.1

RELATED PARTY TRANSACTIONS (Tables) | 12 Months Ended
--- | ---
Mar. 31, 2026
Notes and other explanatory information [abstract] |
Schedule of compensation payable |
Schedule of compensation payable |  |  |  |  |  |  |  |  |  |  |  |
Years ended March 31, |  | 2026 |  | 2025 |  | 2024
Short-term employee benefits (salary, bonus, etc.) |  |  | 4,052 |  |  |  | 13,787 |  |  |  | 2,127 |
Post-employment benefits |  |  |  |  |  |  |  |  |  |  |  |
Other long-term benefits |  |  |  |  |  |  |  |  |  |  |  |
Termination benefits |  |  | 152 |  |  |  |  |  |  |  | 49 |
Share-based payment compensation |  |  | 1,600 |  |  |  | 590 |  |  |  |  |
Total |  |  | 5,804 |  |  |  | 1,968 |  |  |  | 2,176 |
Schedule of Compensation |
Schedule of Compensation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Name & Principal Position |  | Year |  | Fee and Salary(1) |  | Bonus |  | Transaction Closing Bonus(3) |  | Securities Under Options Granted |  | Shares or Units(16) |  | Other(3) |  | Total Compensation
|  |  |  |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |
Michael Terpin |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | 61,250 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 61,250 |
F. Daniel Siciliano |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | 17,500 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 17,500 |
Gregory H. Bailey, M.D.(6) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | 30,000 |  |  |  | 25,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 55,000 |
|  |  | 2025 |  |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 30,000 |
|  |  | 2024 |  |  |  | 49,500 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 49,500 |
James Mellon(6) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | 30,000 |  |  |  | 25,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 55,000 |
|  |  | 2025 |  |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 30,000 |
|  |  | 2024 |  |  |  | 35,242 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 35,242 |
Steven Mintz(8) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | 77,500 |  |  |  | 25,000 |  |  |  | - |  |  |  | 54,796 |  |  |  | - |  |  |  | - |  |  |  | 157,296 |
|  |  | 2025 |  |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | 113,158 | (5) |  |  | - |  |  |  | - |  |  |  | 143,158 |
|  |  | 2024 |  |  |  | 45,750 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 45,750 |
Jean-Christophe Renondin, M.D.(7) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | 30,000 |  |  |  | 25,000 |  |  |  | - |  |  |  | 54,796 |  |  |  | - |  |  |  | - |  |  |  | 109,796 |
|  |  | 2025 |  |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | 96,992 | (5) |  |  | - |  |  |  | - |  |  |  | 126,992 |
|  |  | 2024 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Justin Stebbing, M.D. PhD(7) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | 30,000 |  |  |  | 25,000 |  |  |  | - |  |  |  | 64,760 |  |  |  | - |  |  |  | - |  |  |  | 119,760 |
|  |  | 2025 |  |  |  | 30,000 |  |  |  | - |  |  |  | - |  |  |  | 121,240 | (5) |  |  | - |  |  |  | - |  |  |  | 151,240 |
|  |  | 2024 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Linda Kozick(9) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
|  |  | 2025 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
|  |  | 2024 |  |  |  | 42,000 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 42,000 |
Mark Simon(9) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
|  |  | 2025 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
|  |  | 2024 |  |  |  | 55,500 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 55,500 |
Robert Glassman(9) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | 2026 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
|  |  | 2025 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
|  |  | 2024 |  |  |  | 45,258 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 45,258 |
Schedule of outstanding equity awards |
Schedule of outstanding equity awards |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Option Awards |  | Stock Awards(6)
|  |  |  | Number of |  |  |  |  |  | Number of Shares or |  | Market Value of Shares or
|  |  |  | Securities Underlying |  | Option |  | Option |  | Units of Stock |  | Units of Stock
|  |  |  | Unexercised Options |  | Exercise |  | Expiration |  | That Have |  | That Have
Name |  | Grant Date |  | Exercisable(1) |  | Unexercisable |  | Price |  | Date |  | Not Vested |  | Not Vested
Alexander Pickett(2) |  | 3/7/2025 |  |  | 36,000 |  |  |  | - |  |  |  | 4.45 |  |  |  | 3/7/2035 |  |  |  | - |  |  |  | - |
|  | 7/27/2025 |  |  | 45,937 |  |  |  | - |  |  |  | 5.73 |  |  |  | 7/27/2035 |  |  |  | - |  |  |  | - |
Ian B. Walters(3) |  | 3/30/2023 |  |  | 15,085 |  |  |  | - |  |  |  | 58.40 |  |  |  | 12/14/2026 |  |  |  | - |  |  |  | - |
|  | 1/19/2022 |  |  | 6,285 |  |  |  | - |  |  |  | 204.40 |  |  |  | 12/14/2026 |  |  |  | - |  |  |  | - |
|  | 1/13/2021 |  |  | 7,550 |  |  |  | - |  |  |  | 355.00 |  |  |  | 12/14/2026 |  |  |  | - |  |  |  | - |
Andrea E. Park(4) |  | 3/7/2025 |  |  | 28,000 |  |  |  | - |  |  |  | 4.45 |  |  |  | 3/7/2035 |  |  |  | - |  |  |  | - |
|  | 7/27/2025 |  |  | 7,820 |  |  |  | - |  |  |  | 5.73 |  |  |  | 7/27/2035 |  |  |  | - |  |  |  | - |
Allan Shaw(5) |  | 3/30/2023 |  |  | 1,761 |  |  |  | - |  |  |  | 58.40 |  |  |  | 9/30/2026 |  |  |  | - |  |  |  | - |
|  | 1/19/2022 |  |  | 840 |  |  |  | - |  |  |  | 204.40 |  |  |  | 9/30/2026 |  |  |  | - |  |  |  | - |
|  | 1/13/2021 |  |  | 6,550 |  |  |  | - |  |  |  | 355.00 |  |  |  | 9/30/2026 |  |  |  | - |  |  |  | - |
Robert Kramer(6) |  | 3/30/2023 |  |  | 2,771 |  |  |  | - |  |  |  | 58.40 |  |  |  | 3/30/2033 |  |  |  | - |  |  |  | - |
|  | 1/19/2022 |  |  | 1,255 |  |  |  | - |  |  |  | 204.40 |  |  |  | 1/19/2032 |  |  |  | - |  |  |  | - |
|  | 1/13/2021 |  |  | 3,050 |  |  |  | - |  |  |  | 355.00 |  |  |  | 1/13/2031 |  |  |  | - |  |  |  | - |
Brian Wiley(7) |  | 3/30/2023 |  |  | 2,386 |  |  |  | - |  |  |  | 58.40 |  |  |  | 11/15/2026 |  |  |  | - |  |  |  | - |
|  | 1/19/2022 |  |  | 3,000 |  |  |  | - |  |  |  | 204.40 |  |  |  | 11/15/2026 |  |  |  | - |  |  |  | - |
Brittany Kaiser(8) |  | 3/11/2026 |  |  | 545,315 |  |  |  | - |  |  |  | 1.30 |  |  |  | 5/14/2036 |  |  |  | - |  |  |  | - |
Enzo Villani(8) |  | 3/11/2026 |  |  | 545,315 |  |  |  | - |  |  |  | 1.30 |  |  |  | 5/14/2036 |  |  |  | - |  |  |  | - |
Yury Mitin(8) |  | 3/11/2026 |  |  | 545,315 |  |  |  | - |  |  |  | 1.30 |  |  |  | 5/14/2036 |  |  |  | - |  |  |  | - |
Notes
| (1) | Except as set forth below, vesting of all options is subject to continued service as an employee, director and/or consultant of Alpha Compute or a subsidiary on the applicable vesting date. One fourth of the options vested or will vest on the first anniversary of the date of grant, and the remaining balance of the options vested or will vest in 36 equal monthly installments thereafter.
| (2) | On December 15, 2024, Mr. Pickett was appointed as a director of the Company and our Chief Executive Officer under a consultancy agreement and served in such capacities through December 19, 2025, his resignation date. These options were awarded to Mr. Pickett for his services as a director. One fourth of the options vested immediately on grant date, and the remaining vest in three equal annual installments thereafter.
| (3) | Dr. Walters served as our Chief Executive Officer and a director of the Company through December 14, 2024. Pursuant to the terms of his employment agreement, all unvested share options immediately vested on such date. Pursuant to the terms of his share option agreements, the vested share options are exercisable for two years from this date.
| (4) | On September 30, 2024, Ms. Park was appointed as our Chief Financial Officer and departed the Company in October 2025. One fourth of the options vested immediately on the grant date, and the remaining vest in three equal annual installments thereafter.
| (5) | Mr. Shaw served as our Chief Financial Officer through September 30, 2024. Pursuant to the terms of his share option agreements, the vested share options are exercisable for two years from such date.
| (6) | The above table excludes 4,550 RSUs to Mr. Kramer granted on January 13, 2021, with a grant date value of $1,615,250, which vested on the grant date but are subject to certain restrictions and 860 RSUs granted on January 19, 2022 with a grant date value of $175,784, which vested on the grant date.
| (7) | Mr. Wiley served as our Chief Business Officer through November 15, 2024. Pursuant to the terms of his employment agreement, all unvested shares immediately vested on such date. Pursuant to the terms of his share option agreement, the vested share options are exercisable for two years from such date.
| (8) | On March 11, 2026, the Board authorized the grant of 545,315 share options each to Ms. Kaiser, Mr. Mitin, and Mr. Villani, which were owed pursuant to their contractor agreements upon the Company raising at least $50 million in equity financing via either private or public share offerings. These share options were formally granted on May 14, 2026.

X
- Definition The disclosure of compensation to the entity's auditors. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfAuditorsRemunerationExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_NotesAndOtherExplanatoryInformationAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ptgef_ScheduleOfCompensationPayableTableTextBlock
Namespace Prefix: | ptgef_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ptgef_ScheduleOfOutstandingEquityAwardsTableTextBlock
Namespace Prefix: | ptgef_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration